NVS acquires CoStim Pharmaceuticals (private) for undisclosed price: http://www.novartis.com/newsroom/media-releases/en/2014/1762334.shtml Novartis announced today that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals Inc., a Cambridge, MA-based, privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer.